SIH Partners LLLP acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,949 shares of the company's stock, valued at approximately $783,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Nordea Investment Management AB bought a new position in shares of AstraZeneca during the fourth quarter worth about $754,000. Diversify Wealth Management LLC grew its position in AstraZeneca by 3.6% in the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company's stock worth $295,000 after purchasing an additional 153 shares during the last quarter. Ameritas Advisory Services LLC raised its holdings in shares of AstraZeneca by 25.9% during the fourth quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company's stock valued at $622,000 after buying an additional 1,949 shares during the last quarter. Oak Ridge Investments LLC boosted its position in shares of AstraZeneca by 5.4% during the fourth quarter. Oak Ridge Investments LLC now owns 143,973 shares of the company's stock worth $9,433,000 after buying an additional 7,341 shares during the period. Finally, Asio Capital LLC increased its position in AstraZeneca by 11.6% in the 4th quarter. Asio Capital LLC now owns 53,541 shares of the company's stock valued at $3,508,000 after acquiring an additional 5,569 shares during the period. Institutional investors and hedge funds own 20.35% of the company's stock.
Wall Street Analysts Forecast Growth
Several analysts have recently weighed in on the company. UBS Group upgraded AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. BNP Paribas assumed coverage on shares of AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective for the company. Finally, Morgan Stanley began coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They issued an "overweight" rating on the stock. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $86.80.
Check Out Our Latest Analysis on AZN
AstraZeneca Stock Up 0.0 %
Shares of AZN traded up $0.02 during trading hours on Friday, reaching $69.57. The company's stock had a trading volume of 6,662,575 shares, compared to its average volume of 5,181,905. The company has a quick ratio of 0.74, a current ratio of 0.93 and a debt-to-equity ratio of 0.65. The firm has a market cap of $215.75 billion, a price-to-earnings ratio of 30.78, a P/E/G ratio of 1.42 and a beta of 0.49. The company has a 50 day moving average of $72.43 and a two-hundred day moving average of $70.30. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $1.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. As a group, research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.
AstraZeneca Increases Dividend
The company also recently announced a semi-annual dividend, which was paid on Monday, March 24th. Shareholders of record on Friday, February 21st were given a $1.03 dividend. This is a positive change from AstraZeneca's previous semi-annual dividend of $0.49. This represents a yield of 2%. The ex-dividend date of this dividend was Friday, February 21st. AstraZeneca's dividend payout ratio is presently 91.15%.
AstraZeneca Company Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
